AXIAL Logo 2021MAR05.png
  • Our Science

  • Our Pipeline

  • About Us

  • Newsroom

  • Careers

  • Contact

  • More

    Use tab to navigate through the menu items.
     

    News Archives

    Archives
    In the News
    Media Inquiries
    Press Releases
    2021
    2020
    2019
    November 30, 2021

    Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

    Button
    October 27, 2021

    Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

    Button
    October 13, 2021

    Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

    Button
    April 15, 2021

    Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit

    Button
    March 8, 2021

    Axial Therapeutics Promotes A. Stewart Campbell to Chief Executive Officer

    Button
    January 6, 2021

    Axial Therapeutics to Present at the Inaugural Virtual H.C. Wainwright BioConnect Conference

    Button
    Our Science
    Technology Platform
    Abstracts
    Our Pipeline
    Autism Spectrum Disorder
    Parkinson's Disease
    About Us
    Leadership
    Board of Directors
    AXIAL Logo 2021MAR05.png
    Newsroom
    Press Releases
    News Archives
    Media Inquiries
    In the News
    Careers
    Join the Team
    Open Positions
    Contact
    General Inquiries

    400 Tradecenter Drive
    Suite 6990
    Woburn, MA 01801


    Phone: +1 781-701-8484

    ​

    info@axialtx.com

    © Axial Therapeutics, Inc. 2021. All rights reserved

    Terms of Use
    Privacy
    Cookies
    Social Media